[1] [1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.

[2] [2] ARBYN M, WEIDERPASS E, BRUNI L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis ［J］. The Lancet Global Health, 2020, 8(2): e191-e203.

[3] [3] KHAN M I, HARIPRASAD G. Structural modeling of wild and mutant forms of human plasma platelet activating factor-acetyl hydrolase enzyme ［J］. Journal of Inflammation Research, 2020, 13: 1125-1139.

[4] [4] ZHENG H, CUI D, QUAN X, et al. Lp-PLA2 silencing protects against ox-LDL-induced oxidative stress and cell apoptosis via Akt/mTOR signaling pathway in human THP1 macrophages ［J］. Biochemical and Biophysical Research Communications, 2016, 477(4): 1017-1023.

[5] [5] HUO J, WU L, ZANG Y. Development and validation of a metabolic-related prognostic model for hepatocellular carcinoma ［J］. Journal of Clinical and Translational Hepatology, 2021, 9(2): 169-179.

[6] [6] LEHTINEN L, VAINIO P, WIKMAN H, et al. PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells ［J］. The Journal of Pathology, Clinical Research, 2017, 3(2): 123-138.

[7] [7] BENLI E, BAYRAK A, CIRAKOGLU A, et al. Comparison of serum acetyl hydrolase (PAF-AH) and paraoxonase 1 (PON1) values between prostate cancer patients and a control group ［J］. The Kaohsiung Journal of Medical Sciences, 2017, 33(11): 572-577.

[8] [8] WU P, HEINS Z J, MULLER J T, et al. Integration and analysis of CPTAC proteomics data in the context of cancer genomics in the cBioPortal ［J］. Molecular and Cellular Proteomics, 2019, 18(9): 1893-1898.

[9] [9] BARRETT T, WILHITE S E, LEDOUX P, et al. NCBI GEO: archive for functional genomics data sets: update ［J］. Nucleic Acids Research, 2013, 41: D991-D995.

[10] [10] TANG Z, LI C, KANG B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses ［J］. Nucleic Acids Research, 2017, 45(W1): W98-W102.

[11] [11] LI T, FAN J, WANG B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells ［J］. Cancer Research, 2017, 77(21): e108-e110.

[12] [12] DAI D, CHEN B, FENG Y, et al. Prognostic value of prostaglandin I2 synthase and its correlation with tumor-infiltrating immune cells in lung cancer, ovarian cancer, and gastric cancer ［J］. Aging, 2020, 12(10): 9658-9685.

[13] [13] BORGES A F, MORATO C I, GOMES R S, et al. Platelet-activating factor increases reactive oxygen species-mediated microbicidal activity of human macrophages infected with Leishmania (Viannia) braziliensis ［J］. Pathogens and Disease, 2017, 75(7): 1-8.

[14] [14] LYU S L, ZENG Z F, GAN W Q, et al. Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation ［J］. Acta Pharmacologica Sinica, 2021, 42(12): 2016-2032.

[15] [15] FRAS Z, TR?AN J, BANACH M. On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management ［J］. Archives of Medical Science, 2020, 17(4): 954-964.

[16] [16] MORIGNY P, KALTENECKER D, ZUBER J, et al. Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy ［J］. Journal Cachexia Sarcopenia and Muscle, 2021, 12(5): 1333-1351.

[17] [17] LOW H, PNG C, LI C, et al. Monocyte-derived factors including PLA2G7 induced by macrophage-nasopharyngeal carcinoma cell interaction promote tumor cell invasiveness ［J］. Oncotarget, 2016, 7(34): 55473-55490.

[18] [18] ZHENG W, LIN Q, ISSAH M A, et al. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma ［J］. BMC Cancer, 2021, 21(1): 927.

[19] [19] LIAO Y, BADMANN S, KALTOFEN T, et al. Platelet-activating factor acetylhydrolase expression in BRCA1 mutant ovarian cancer as a protective factor and potential negative regulator of the Wnt signaling pathway ［J］. Biomedicines, 2021, 9(7): 706.

[20] [20] YOSHIHARA K, SHAHMORADGOLI M, MARTíNEZ E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data ［J］. Nature Communications, 2013, 4: 2612.

[21] [21] LAKE C M, VOSS K, BAUMAN B M, et al. TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1 ［J］. Cell Death and Disease, 2021, 12(4): 400-417.